Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company^™, announces the formation of its Scientific Advisory Board. Comprised of distinguished experts in proteomics, genomics, bioinformatics, chemistry, and engineering, the board will play a critical role in shaping Quantum-Si’s scientific and development strategy, identifying emerging trends and applications, and strengthening engagement within the scientific community.

Dr. Gloria M. Sheynkman, a leading expert in proteoform characterization and single-molecule protein sequencing, has been named Chair of the Scientific Advisory Board. Dr. Sheynkman is an Assistant Professor at the University of Virginia with joint appointments in Molecular Physiology and Biological Physics, and Biochemistry and Molecular Genetics. Her research integrates advanced mass spectrometry, long-read RNA sequencing, and single-molecule protein sequencing to map and characterize diverse proteoforms, providing new insights into complex diseases such as cardiovascular disease and cancer. A recipient of numerous awards, she is actively involved in key professional organizations, including the American Society for Mass Spectrometry (ASMS) and the Human Proteome Organization (HUPO).

"Proteomics is entering a transformative era, and I’m thrilled to collaborate with Quantum-Si in advancing the tools needed to explore its full complexity. It is opening new doors for understanding proteoforms, complementing mass spectrometry and poised to reveal insights we previously couldn’t access. I look forward to contributing to Quantum-Si’s mission and driving innovation in the field,” said Dr. Sheynkman.

“We are honored to welcome Dr. Sheynkman as Chair of our Scientific Advisory Board, along with an esteemed group of advisors who bring deep expertise in proteomics and single-molecule sequencing,” said Jeff Hawkins, Chief Executive Officer of Quantum-Si. “Their guidance will be invaluable as we continue to advance proteomics through innovation in NGPS and beyond. As we expand our technology portfolio with Proteus™ and other future developments, their expertise will help guide us in unlocking new applications and broadening the impact of our solutions across life sciences.”

Joining Dr. Sheynkman on the SAB are:

• Dr. Benjamin A. Garcia – A globally recognized leader in mass spectrometry-based proteomics, Dr. Garcia is the Raymond H. Wittcoff Distinguished Professor and Head of the Department of Biochemistry and Molecular Biophysics at Washington University School of Medicine in St. Louis. His research focuses on developing novel proteomic and bioinformatics approaches to study protein modifications and their role in epigenetic regulation and disease. He has published over 450 scientific papers and holds leadership positions in HUPO, US HUPO, ASMS, and the ACS.

• Dr. Bradley L. Pentelute – A Professor of Chemistry at Massachusetts Institute of Technology (MIT) and an Associate Member of the Broad Institute of Harvard and MIT, Dr. Pentelute’s research explores peptide and protein synthesis, bioengineering, and molecular delivery systems. His expertise in chemical biology and peptide therapeutics brings a valuable perspective to Quantum-Si’s efforts to expand protein sequencing applications.

• Dr. Denis Zaccarin – A seasoned expert in semiconductor technology and consumable development for sequencing platforms, Dr. Zaccarin previously held senior leadership positions at Pacific Biosciences of California (PacBio), including Senior Vice President of Research and Development. With extensive experience in engineering and optical systems, he will provide strategic insights into the development of Quantum-Si’s next-generation technology.

The Scientific Advisory Board will support Quantum-Si in prioritizing key applications, fostering collaborations, and driving awareness of NGPS within the broader scientific community.

For more information about Quantum-Si’s new advisors, visit: Scientific Advisory Board Team | Quantum-Si

About Quantum-Si Incorporated

Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company’s Platinum^® line of instruments enables Next-Gen Protein Sequencing™ that advances proteomic research, drug discovery, and diagnostics beyond what has been possible with existing proteomic tools. Learn more at quantum-si.com or follow us on LinkedIn or X.

Forward Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s expectations with respect to future performance and development and commercialization of products and services, its anticipated cash runway and its financial guidance for the full year 2024. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the inability to maintain the listing of the Company’s Class A common stock on The Nasdaq Stock Market; the ability of the Company to grow and manage growth profitably and retain its key employees; the Company’s ongoing leadership transitions; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company’s product development and commercialization activities; the commercialization and adoption of the Company’s existing products and the success of any product the Company may offer in the future; the potential attributes and benefits of the Company’s commercialized Platinum® protein sequencing instruments and kits and the Company’s other products once commercialized; the Company’s ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company’s ability to identify, in-license or acquire additional technology; the Company’s ability to maintain its existing lease, license, manufacture and supply agreements; the Company’s ability to compete with other companies currently marketing or engaged in the development or commercialization of products and services that serve customers engaged in proteomic analysis, many of which have greater financial and marketing resources than the Company; the size and growth potential of the markets for the Company’s products and services, and its ability to serve those markets once commercialized, either alone or in partnership with others; the Company’s estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company’s financial performance; and other risks and uncertainties described under “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and in the Company’s other filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250204545680/en/